Since YARS overexpression was verified as a strong biomarker predicting good response to chemotherapy in the breast cancer patient cohort, we established YARS-overexpressing cell models (Supplementary Fig. S2) to explore further the biological functions of YARS and how it affects chemotherapeutic efficacy. Here, YARS1 is linked to breast carcinoma.